Research ArticleNEUROSCIENCE

Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA–induced dyskinesia

See allHide authors and affiliations

Science Advances  06 Jan 2021:
Vol. 7, no. 2, eabe5948
DOI: 10.1126/sciadv.abe5948

Article Information

vol. 7 no. 2

Online ISSN: 
  • Received for publication September 1, 2020
  • Accepted for publication November 10, 2020
  • .

Author Information

  1. Elva Fridjonsdottir1,
  2. Reza Shariatgorji1,2,
  3. Anna Nilsson1,2,
  4. Theodosia Vallianatou1,
  5. Luke R. Odell3,
  6. Luke S. Schembri1,2,
  7. Per Svenningsson4,
  8. Pierre-Olivier Fernagut5,6,7,
  9. Alan R. Crossman8,
  10. Erwan Bezard5,6,9,* and
  11. Per E. Andrén1,2,*
  1. 1Medical Mass Spectrometry Imaging, Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.
  2. 2Science for Life Laboratory, National Resource for Mass Spectrometry Imaging, Uppsala University, Uppsala, Sweden.
  3. 3Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
  4. 4Section of Neurology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  5. 5Université de Bordeaux, Institut des Maladies Neurodégénératives, Bordeaux, France.
  6. 6CNRS, Institut des Maladies Neurodégénératives, Bordeaux, France.
  7. 7Université de Poitiers, INSERM, U0-1084, Laboratoire de Neurosciences Expérimentales et Cliniques, Poitiers, France.
  8. 8University of Manchester, Manchester M13 9PL, UK.
  9. 9Motac Neuroscience, Manchester M15 6WE, UK.
  1. *Corresponding author. Email: erwan.bezard{at} (E.B.); per.andren{at} (P.E.A.)


Article usage

Article usage: January 2021 to May 2021

Jan 20212072639652
Feb 202163495205
Mar 202118535151
Apr 2021366890
May 2021023220

Stay Connected to Science Advances

Navigate This Article